Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEFORE-S: Belimumab in Early Systemic Lupus Erythematosus
jRCTs021210042Completed
- Sponsor
- GSK
- Start
- Jan 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Randomised, double-blind trial in systemic lupus erythematosus (SLE) comparing Belimumab + standard of care with Placebo + standard of care (2 arms). Primary endpoint: Distribution of LLDAS maintenance period over 48 weeks after end of administration. Started Jan 2022; status: completed.
02
Drugs
belimumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on jRCTs021210042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs021210042.